Navigation Links
Actavis and Warner Chilcott Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Warner Chilcott
Date:9/27/2013

PARSIPPANY, N.J. and DUBLIN, Sept. 27, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) and Warner Chilcott plc (NASDAQ: WCRX) today announced that the U.S. Federal Trade Commission (FTC) has voted to approve Actavis' proposed acquisition of Warner Chilcott.  The vote in support of the transaction follows Actavis' agreement to a proposed consent order, pursuant to which Actavis has agreed to divest certain products as a condition to obtaining FTC approval.  The closing of the transaction remains subject to approval by the Irish High Court and other customary closing conditions, and is expected to occur as soon as practicable after satisfaction of those conditions.

Under the terms of the consent order with the FTC and subject to the consummation of the transaction between Actavis and Warner Chilcott, Actavis will divest four products to Amneal Pharmaceuticals.  Terms of the divestitures were not disclosed.  The divested products are:

  • Actavis' Zenchent Fe™ (norethindrone acetate/ethinyl estradiol), a generic version of Femcon Fe™
  • Actavis' pending application for norethindrone acetate/ethinyl estradiol, a generic version of Lo Loestrin® Fe. This product application remains subject to pending patent litigation pursuant to the provisions of the Hatch Waxman Act
  • Actavis' pending application for risedronate sodium, a generic version of Atelvia®. This product application remains subject to pending patent litigation pursuant to the provisions of the Hatch Waxman Act
  • Actavis' approved application for norethindrone acetate/ethinyl estradiol, a generic version of Loestrin®'/>"/>

  • SOURCE Actavis, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related medicine technology :

    1. Actavis, Inc. to Host Third Quarter 2013 Earnings Conference Call and Webcast
    2. Successful Clinical Trials, Recognitions, Enrollment in Studies, Product Launches, and Strategic Announcements - Research Report on Boston Scientific, Gilead, Abbott, Actavis, and Covidien
    3. Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis
    4. Actavis Proposed Acquisition of Warner Chilcott Recommended for Approval by Leading Proxy Advisory Firms
    5. Actavis Names James DArecca Chief Accounting Officer
    6. Actavis Receives Approval from French Competition Authority for Pending Warner Chilcott Acquisition
    7. Actavis Announces New Senior Unsecured Term Loan Credit and Guaranty Agreement
    8. Actavis and Warner Chilcott Announce Effectiveness of Registration Statement on Form S-4
    9. Actavis Announces 42% Increase to $2.01 in Second Quarter 2013 Non-GAAP Earnings Per Share
    10. Actavis and Warner Chilcott Receive FTC Second Request Under Hart-Scott-Rodino
    11. Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... 2014  Zafgen, Inc., a leading biopharmaceutical company dedicated ... patients, today announced initial results from its Phase ... methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi ...  These results showed improvements in body weight, hunger-related ...
    (Date:1/14/2014)... 14, 2014 HeartWare International, Inc . (NASDAQ: ... invasive, miniaturized circulatory support technologies that are revolutionizing the ... expects revenues for the fourth quarter of 2013 will ... to approximately $208 million. "Our full-year revenue ...
    (Date:1/14/2014)... Jan. 14, 2014 InformEx, North America,s ... high-value chemistry, will hold the 30 th edition of ... Convention Center from January 21-24. (Logo: ... top pharmaceutical, fine chemical and specialty chemical companies will take ...
    Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
    ... Be a More Effective Monitor Than, Hemoglobin A1C of ... ... FRANCISCO, June 7 GlycoMark, Inc. announced today,results from ... test is a better reflection of glucose, particularly after-meal,glucose ...
    ... SAN FRANCISCO, California, June 6 , - ... results from the world,s largest ever study of ... using modified release,gliclazide and other drugs as required, ... particular, intensive treatment reduces,the risk of kidney disease ...
    Cached Medicine Technology:DURABLE Clinical Trial Results Show GlycoMark is Key Test for Managing Patients with Diabetes 2DURABLE Clinical Trial Results Show GlycoMark is Key Test for Managing Patients with Diabetes 3The Largest Ever Study of Diabetes Shows Intensive Glucose Control Reduces Serious Complications 2
    (Date:7/9/2014)... OH, July 10, 2014 -- The World Health Organization ... minutes of moderate to vigorous physical activity (MVPA) each ... of their MVPA during school hours. Therefore, it ... hours would increase MVPA. In a new study ... , researchers confirmed that time spent outdoors after school ...
    (Date:7/9/2014)... TORONTO, July 10, 2014 For the first time, ... urban Aboriginal population in Canada uses health care. A ... database to clearly demonstrate the unique challenges faced by ... at St. Michael,s Hospital. , The findings, published ... between urban First Nations individuals and the general population. ...
    (Date:7/9/2014)... the Perelman School of Medicine at the University of ... have received an $8 million grant from the National ... light therapy (PDT) in patients with malignant pleural mesothelioma, ... manifests itself in the lining of the lungs and ... grant will fund a clinical trial and additional studies ...
    (Date:7/9/2014)... A network of signals active in almost all types ... into overdrive, and may help fuel a tumour,s uncontrolled ... of Cancer Research, London, identified a molecular trigger responsible ... the cellular factory that makes the building blocks ... in the TOR signalling pathway, called SREBP, controls the ...
    (Date:7/9/2014)... Studying the most common type of lung cancer, researchers ... a role in forming tumors. The new knowledge may ... these genetic changes already are available or are in ... , investigators from The Cancer Genome Atlas (TCGA), including ... Louis, Harvard Medical School and other institutions, studied tumors ...
    Breaking Medicine News(10 mins):Health News:Go play outside! Outdoor time promotes physical activity in youth 2Health News:Urban Aboriginal people face unique health challenges 2Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Lung cancer study hints at new treatments 2
    ... Reporter , MONDAY, Feb. 28 (HealthDay News) -- The battle of ... players in the fight to reduce waistlines, two new studies report. ... told by their doctors that they are overweight or obese, they ... likely to want to lose weight and to try to lose ...
    ... State University School of Medicine physician-researcher has developed a ... The treatment is based on a naturally occurring human ... cells into killing themselves. The unique concept, patented ... cells that are resistant to routine treatments such as ...
    ... Feb. 28, 2011 Los Angeles Biomedical Research ... Inc., a Japanese biotechnology firm, have entered into a ... in regenerative medicine, "Cell Sheet Engineering," LA BioMed President ... "LA BioMed is working to accelerate the pace of ...
    ... , A new University of Colorado Boulder study indicates ... in helping to treat people with mild traumatic brain ... U.S. war veterans returning home. The study involved ... are used to stimulate particular points on a person,s ...
    ... (BUSM) have found that patients with node negative T3 ... surgery had more than three times the survival rate ... appear on-line in the Journal of Thoracic and ... total of 110 patients who underwent surgical resection for ...
    ... brain imaging study at the U.S. Department of Energy,s (DOE) ... subjects and those who compulsively overeat, or binge: In binge ... smell of favorite foods triggers a spike in dopamine - ... - published online on February 24, 2011, in the journal ...
    Cached Medicine News:Health News:Doctors Can Influence Patients to Lose Weight: Studies 2Health News:Doctors Can Influence Patients to Lose Weight: Studies 3Health News:WSU researcher creates patented personalized therapy that causes cancer cells to kill themselves 2Health News:WSU researcher creates patented personalized therapy that causes cancer cells to kill themselves 3Health News:WSU researcher creates patented personalized therapy that causes cancer cells to kill themselves 4Health News:LA BioMed and CellSeed to launch joint research project on regenerative medicine technology 2Health News:U. of Colorado study shows acupressure effective in helping to treat traumatic brain injury 2Health News:U. of Colorado study shows acupressure effective in helping to treat traumatic brain injury 3Health News:U. of Colorado study shows acupressure effective in helping to treat traumatic brain injury 4Health News:Binge eaters' dopamine levels spike at sight, smell of food 2Health News:Binge eaters' dopamine levels spike at sight, smell of food 3
    ... a single use rapid test, for the detection ... whole blood (venipuncture). Uni-Gold Recombigen HIV is intended ... an aid in diagnosis of infection with HIV-1. ... multi-test algorithms designed for the statistical validation of ...
    ... HIV-1 Oral Specimen Collection Device is a safe, ... antibodies. Testing with the OraSure HIV-1 Oral Specimen ... has been shown to be more than 99% ... cotton fiber pad attached to a nylon stick ...
    The Becton™ Colles Fracture Plate has proven clinical outcomes and has excellent patient acceptance compared to external fixation. It provides a cost effective treatment option through a simple...
    ... Angle CHS System takes the time proven ... , ,The VHS® Supracondylar Cable Plate is ... distal femur fractures including periprosthetic fractures. The ... variable angle of the barrel and the ...
    Medicine Products: